NCT01169714 - A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Healthy

Interventions

DRUG

0.1 mg PF-04995274

0.1 mg PF-04995274, qd, for 14 days or placebo

DRUG

1 mg PF-04995274

1 mg PF-04995274, qd, for 14 days or placebo

DRUG

10 mg PF-04995274

10 mg PF-04995274, qd, for 14 days or placebo

DRUG

15 mg PF-04995274

15 mg PF-04995274, qd, for 14 days or placebo

DRUG

1.0 mg PF-04995274

1.0 mg PF-04995274, qd, for 14 days or placebo

DRUG

15 mg PF-04995274

15 mg PF-04995274, qd, for 14 days or placebo

Trial Locations (2)

Pfizer Investigational Site, Overland Park

Pfizer Investigational Site, Overland Park